February 21, 2025 04:54 AM ESTUpdated 11:23 AM

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Kyle LaHucik

Senior Reporter

Concentra Biosciences, the shell company from Tang Capital that tries to buy out struggling biotechs, has found another target, this time trying to throw a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger